Abstract: A manufacturing method is disclosed herein. The method includes arranging a preform over a surface of an inner mold line; folding the preform over sides of the inner mold line; pressing an end of the preform into a grip strip coupled to a side of the inner mold line; and applying pressure to the preform to force excess material of the preform into a forming bead of the inner mold line.

Abstract: A method of assembling and installing an underwing package to an underside of an aircraft wing is disclosed. In various embodiments, the method includes assembling the underwing package, comprising at least a pylon and an engine, using a build frame; attaching a transfer cart to the underwing package; lowering the underwing package and the transfer cart from the build frame; transporting the underwing package and the transfer cart to the underside of the aircraft wing; and transferring the underwing package from the transfer cart to the underside of the aircraft wing.

Abstract: A method of assembling and installing an underwing package to an underside of an aircraft wing is disclosed. In various embodiments, the method includes assembling the underwing package, comprising at least a pylon and an engine, using a build frame; attaching a transfer cart to the underwing package; lowering the underwing package and the transfer cart from the build frame; transporting the underwing package and the transfer cart to the underside of the aircraft wing; and transferring the underwing package from the transfer cart to the underside of the aircraft wing.

Abstract: The present invention relates to certain (1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl carboxylic acid derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, sepsis, myocardial infarction, ischemic stroke, acne, microbial infections or diseases and viral infections or diseases.

Abstract: The present invention relates to certain (1,2,4-oxadiazol-3-yl)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl carboxylic acid derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, microbial infections or diseases and viral infections or diseases.